trending Market Intelligence /marketintelligence/en/news-insights/trending/z1vHWp9yKsPgm8mu3aERKg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Erytech Pharma shares plummet as cancer drug fails in clinical trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Erytech Pharma shares plummet as cancer drug fails in clinical trial

Erytech Pharma Société Anonyme shares dropped 30.62% on Dec. 8 after the failure of the French company's Graspa cancer drug in a phase 2b trial.

The results from the trial showed that Graspa in combination with low-dose cytarabine was no better than low-dose cytarabine alone for the treatment of acute myeloid leukemia, or AML, in older and frail patients.

The combination treatment did not meet the main goal of overall survival and also missed secondary goals that included progression-free survival, or the length of time patients live without their disease worsening, and overall response to therapy.

The drug met a secondary endpoint related to toxicity, which the company said was at an acceptable level and consistent with previously reported data for the drug.

Erytech Pharma said the trials included 123 patients over the age of 65 who were newly diagnosed with AML and could not endure intensive chemotherapy.

The study was performed in collaboration with Orphan Europe, a subsidiary of Recordati SpA, Erytech's partner for the anticipated commercialization of Graspa for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia in Europe. Recordati shares rose 1.66% on Dec. 8.